YQ128

YQ128
Identifiers
	IUPAC name N-[(5-chloro-2-propoxyphenyl)methyl]-N-[2-[4-(prop-2-ynylsulfamoyl)phenyl]ethyl]-2-thiophen-3-ylacetamide;
CAS Number	2454246-18-3;
PubChem CID	139600339;
ChemSpider	84442926;
ChEMBL	ChEMBL4559751;
Chemical and physical data
Formula	C27H29ClN2O4S2
Molar mass	545.11 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCOC1=C(C=C(C=C1)Cl)CN(CCC2=CC=C(C=C2)S(=O)(=O)NCC#C)C(=O)CC3=CSC=C3;
	InChI InChI=1S/C27H29ClN2O4S2/c1-3-13-29-36(32,33)25-8-5-21(6-9-25)11-14-30(27(31)17-22-12-16-35-20-22)19-23-18-24(28)7-10-26(23)34-15-4-2/h1,5-10,12,16,18,20,29H,4,11,13-15,17,19H2,2H3; Key:SFPYRFRNYALLHS-UHFFFAOYSA-N;

YQ128 is an experimental drug which acts as an inhibitor of the NLRP3 inflammasome. It inhibits the release of interleukin-1β and interleukin-18 which is usually triggered by inflammatory stimuli, and so terminates the resulting signalling cascade. It has antiinflammatory effects and good brain penetration, and is being researched for potential applications in conditions such as Alzheimer's disease and traumatic brain injury.^[1]^[2]

References

↑ Jiang Y, He L, Green J, Blevins H, Guo C, Patel SH, et al. (November 2019). "Discovery of Second-Generation NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization". Journal of Medicinal Chemistry. 62 (21): 9718–9731. doi:10.1021/acs.jmedchem.9b01155. PMC 6856409. PMID 31626545.
↑ Xu Y, Xu Y, Blevins H, Guo C, Biby S, Wang XY, et al. (August 2022). "Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies". European Journal of Medicinal Chemistry. 238 114468. doi:10.1016/j.ejmech.2022.114468. PMC 10084479. PMID 35635948.

[pmid31626545-1] Jiang Y, He L, Green J, Blevins H, Guo C, Patel SH, et al. (November 2019). "Discovery of Second-Generation NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization". Journal of Medicinal Chemistry. 62 (21): 9718–9731. doi:10.1021/acs.jmedchem.9b01155. PMC 6856409. PMID 31626545.

[pmid35635948-2] Xu Y, Xu Y, Blevins H, Guo C, Biby S, Wang XY, et al. (August 2022). "Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies". European Journal of Medicinal Chemistry. 238 114468. doi:10.1016/j.ejmech.2022.114468. PMC 10084479. PMID 35635948.

[1]

[2]

See also

References